The aim of the study was to examine the effectiveness of the oxidized form of nicotinamide adenine dinucleotide (NAD+), adenosine precursor, in 37 patients suffering from psoriasis. As NAD+ is known to be relatively unstable, the second goal was to establish the proper conditions for the satisfactory stability of topical NAD+ composition. In each patient, two matching plaques were selected for the study. Topical treatment with 1 or 0.3% NAD+ in Vaseline ointment administered twice daily was compared with overnight therapy with 0.1% anthralin applied for 12 h and placebo. The enzymatic method was applied to determine the stability of NAD+ in Vaseline ointment. After a 4-week application, the reduction in erythema, infiltration and desquamation caused by 1 or 0.3% topical NAD+ composition was similar to the reduction caused by 0.1% anthralin. It was demonstrated that NAD+ underwent a considerable decomposition at room temperature, while it was sufficiently stable at 5°C; thus, for a longer use the agent should be stored at fridge temperature. NAD+ therapy combines good efficacy, cosmetic acceptability and convenient twice-daily application.

Keywords:
Nicotinamide adenine dinucleotide, Psoriasis, Antipsoriatic therapy
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.